NCT02534311View on ClinicalTrials.gov

A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

December 1, 2015

Study Completion Date

December 1, 2015

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

Tocilizumab will be administered at 162 mg SC injection for 48 weeks.

Trial Locations (5)

975 17

Banská Bystrica

813 69

Bratislava

826 06

Bratislava

950 01

Nitra

921 01

Piešťany

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02534311 - A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28) | Biotech Hunter | Biotech Hunter